(Q38005193)

26 August 2017

title

Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis (English)

1 reference

26 August 2017

0 references

Kenji Chiba

1

1 reference

26 August 2017

Kunitomo Adachi

series ordinal

2

1 reference

26 August 2017

publication date

1 April 2012

1 reference

Future Medicinal Chemistry

26 August 2017

published in

1 reference

26 August 2017

volume

4

1 reference

26 August 2017

issue

6

1 reference

26 August 2017

page(s)

771-781

1 reference

Simple compounds, 2-alkyl-2-amino-1,3-propanediols have potent immunosuppressive activity

26 August 2017

cites work

1 reference

Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a novel immunosuppressant, FTY720

21 January 2018

1 reference

Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols

21 January 2018

1 reference

Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin

21 January 2018

1 reference

Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720) in cynomolgus monkeys after single oral and intravenous doses

21 January 2018

1 reference

FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors

21 January 2018

1 reference

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

21 January 2018

1 reference

FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function.

21 January 2018

1 reference

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

21 January 2018

1 reference

Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs

21 January 2018

1 reference

Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit

21 January 2018

1 reference

Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3.

21 January 2018

1 reference

S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress

21 January 2018

1 reference

Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases

21 January 2018

1 reference

The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2

21 January 2018

1 reference

Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists

21 January 2018

1 reference

FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity

21 January 2018

1 reference

Sphingosine 1-phosphate signalling via the endothelial differentiation gene family of G-protein-coupled receptors

21 January 2018

1 reference

Lysophospholipids--receptor revelations

21 January 2018

1 reference

Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells

21 January 2018

1 reference

Immunosuppressive activity of FTY720, sphingosine 1-phosphate receptor agonist: I. Prevention of allograft rejection in rats and dogs by FTY720 and FTY720-phosphate

21 January 2018

1 reference

Asymmetric synthesis and biological evaluation of the enantiomeric isomers of the immunosuppressive FTY720-phosphate.

21 January 2018

1 reference

Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis

21 January 2018

1 reference

Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL mice

21 January 2018

1 reference

Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions

21 January 2018

1 reference

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

21 January 2018

1 reference

Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells.

21 January 2018

1 reference

Mixed results with modulation of TH-17 cells in human autoimmune diseases

21 January 2018

1 reference

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

21 January 2018

1 reference

IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition.

21 January 2018

1 reference

Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment

21 January 2018

1 reference

Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis

21 January 2018

1 reference

Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.

21 January 2018

1 reference

Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients.

21 January 2018

1 reference

Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study

21 January 2018

1 reference

FTY720 (fingolimod) in renal transplantation.

21 January 2018

1 reference

Immunological aspects of demyelinating diseases

21 January 2018

1 reference

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

Axonal injury in multiple sclerosis

21 January 2018

1 reference

Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis.

21 January 2018

1 reference

Immune tolerance to myelin proteins.

21 January 2018

1 reference

Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis

21 January 2018

1 reference

Oral fingolimod (FTY720) for relapsing multiple sclerosis

21 January 2018

1 reference

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

21 January 2018

1 reference

Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis

21 January 2018

1 reference

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor

21 January 2018

1 reference

VEGF induces S1P1 receptors in endothelial cells: Implications for cross-talk between sphingolipid and growth factor receptors

21 January 2018

1 reference

Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology

21 January 2018

1 reference

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation

21 January 2018

1 reference

KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts

21 January 2018

1 reference

Removal of sphingosine 1-phosphate receptor-3 (S1P(3)) agonism is essential, but inadequate to obtain immunomodulating 2-aminopropane-1,3-diol S1P(1) agonists with reduced effect on heart rate

21 January 2018

1 reference

Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate

21 January 2018

1 reference

Cell type-specific localization of human cardiac S1P receptors

21 January 2018

1 reference

A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists

21 January 2018

1 reference

Highly selective and potent agonists of sphingosine-1-phosphate 1 (S1P1) receptor.

21 January 2018

1 reference

Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists

21 January 2018

1 reference

Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors

21 January 2018

1 reference

Design and synthesis of selective and potent orally active S1P5 agonists.

21 January 2018

1 reference

Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.47.208

Identifiers

DOI

10.4155/FMC.12.25

1 reference

26 August 2017

1 reference